SARS-CoV-2—The Autoimmune Virus Is Still Striking

Naim Mahroum; Yehuda Shoenfeld

doi:10.53941/jmai.2025.100001

Journal of Mosaic of Autoimmunity ›› 2025, Vol. 1 ›› Issue (1) :1 DOI: 10.53941/jmai.2025.100001

Editorial

research-article

SARS-CoV-2—The Autoimmune Virus Is Still Striking

Naim Mahroum ¹^,^*
, Yehuda Shoenfeld ²^,³

Author information +

History +

PDF (653KB)

Abstract

While the pandemic of COVID-19 has ended according to the WHO, new emerging cases are still documented worldwide. In addition, due to the huge number of recovered individuals, the sequelae of COVID-19 constitute a real challenge for the medical community. Of importance, is the autoimmune-nature of SARS-CoV-2. Hereby, in our editorial we aimed to shed light over the autoimmune aspects of COVID-19. Understanding the aspects presented aid in the early detection and management of affected patients.

Keywords

infection and autoimmunity / autoimmunity / autoantibodies / SARS-CoV-2 / COVID-19

Cite this article

Download citation ▾

Naim Mahroum, Yehuda Shoenfeld. SARS-CoV-2—The Autoimmune Virus Is Still Striking. Journal of Mosaic of Autoimmunity, 2025, 1 (1) : 1 DOI:10.53941/jmai.2025.100001

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Mahroum, N.; Alghory, A.; Kiyak, Z.; Alwani, A.; Seida, R.; Alrais, M.; Shoenfeld, Y. Ferritin–from iron, through inflammation and autoimmunity, to COVID-19. J. Autoimmun. 2022, 126, 102778. https://doi.org/10.1016/j.jaut.2021.102778.

[2]	Rosario, C.; Zandman-Goddard, G.; Meyron-Holtz, E.G.; D’Cruz, D.P.; Shoenfeld, Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013, 11, 185. https://doi.org/10.1186/1741-7015-11-185.

[3]

Mahroum, N.; Elsalti, A.; Al Shawaf, M.; Darkhabani, M.; Alwani, A.; Seida, R.; Ertas, M.T.; Simsek, A.G.; Awad, M.; Habra, M.; et al. Artificial intelligence meets the world experts; updates and novel therapies in autoimmunity–The 14th international congress on autoimmunity 2024 (AUTO14), Ljubljana. Autoimmun. Rev. 2024, 24, 103698. https://doi.org/10.1016/j.autrev.2024.103698.

[4]	Barzilai, O.; Sherer, Y.; Ram, M.; Izhaky, D.; Anaya, J.M.; Shoenfeld, Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann. N. Y. Acad. Sci. 2007, 1108, 567-577. https://doi.org/10.1196/annals.1422.059.

[5]

Mahroum, N.; Elsalti, A.; Alwani, A.; Seida, I.; Alrais, M.; Seida, R.; Esirgun, S.N.; Abali, T.; Kiyak, Z.; Zoubi, M.; et al. The mosaic of autoimmunity–Finally discussing in person. The 13(th) international congress on autoimmunity 2022 (AUTO13) Athens. Autoimmun. Rev. 2022, 21, 103166. https://doi.org/10.1016/j.autrev.2022.103166.

[6]

Damoiseaux, J.; Dotan, A.; Fritzler, M.J.; Bogdanos, D.P.; Meroni, P.L.; Roggenbuck, D.; Goldman, M.; Landegren, N.; Bastard, P.; Shoenfeld, Y.; et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun. Rev. 2022, 21, 103012. https://doi.org/10.1016/j.autrev.2021.103012.

[7]	Gracia-Ramos, A.E.; Martin-Nares, E.; Hernandez-Molina, G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells 2021, 10, 3592. https://doi.org/10.3390/cells10123592.

[8]	Mahroum, N.; Habra, M.; Alrifaai, M.A.; Shoenfeld, Y. Antiphospholipid syndrome in the era of COVID-19–Two sides of a coin. Autoimmun. Rev. 2024, 103543. https://doi.org/10.1016/j.autrev.2024.103543.

[9]	Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 2021, 93, 250-256. https://doi.org/10.1002/jmv.26232.

[10]

Fernandez-Cruz, A.; Ruiz-Antoran, B.; Munoz-Gomez, A.; Sancho-Lopez, A.; Mills-Sanchez, P.; Centeno-Soto, G.A.; Blanco-Alonso, S.; Javaloyes-Garachana, L.; Galan-Gomez, A.; Valencia-Alijo, A.; et al. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob. Agents Chemother. 2020, 64, 01168-20. https://doi.org/10.1128/AAC.01168-20.

[11]

Li, J.; Liao, X.; Zhou, Y.; Wang, L.; Yang, H.; Zhang, W.; Zhang, Z.; Kang, Y. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock 2021, 56, 215-228. https://doi.org/10.1097/SHK.0000000000001738.

[12]	World Health Organization. WHO COVID-19 Dashboard; World Health Organization: Geneva, Switzerland, 2024.

[13]	Acosta-Ampudia, Y.; Monsalve, D.M.; Rojas, M.; Rodriguez, Y.; Zapata, E.; Ramirez-Santana, C.; Anaya, J.M. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J. Infect. Dis. 2022, 225, 2155-2162. https://doi.org/10.1093/infdis/jiac017.

[14]	Anaya, J.M.; Herran, M.; Beltran, S.; Rojas, M. Is post-COVID syndrome an autoimmune disease? Expert Rev. Clin. Immunol. 2022, 18, 653-666. https://doi.org/10.1080/1744666X.2022.2085561.

[15]	Hulscher, N.; Hodkinson, R.; Makis, W.; McCullough, P.A. Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. ESC Heart Fail. 2024. https://doi.org/10.1002/ehf2.14680.

[16]

Mahroum, N.; Lavine, N.; Ohayon, A.; Seida, R.; Alwani, A.; Alrais, M.; Zoubi, M.; Bragazzi, N.L. COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review. Front. Immunol. 2022, 13, 872683. https://doi.org/10.3389/fimmu.2022.872683.